Lower-dose dexamethasone can be used to treat newly diagnosed myeloma

October 21, 2009

High-dose dexamethasone is a mainstay of therapy for multiple myeloma. However, a study published Online First by the Lancet Oncology concludes that lenalidomide plus low-dose dexamethasone is associated with better short-term overall survival and with lower toxicity than lenalidomide plus high-dose dexamethasone in patients with newly diagnosed myeloma; and is thus a viable treatment option for these patients. The Article is written by Professor S Vincent Rajkumar, Mayo Clinic, Rochester, MN, USA, and colleagues on behalf of the Eastern Cooperative Oncology Group (ECOG), USA.

In this randomised controlled trial, patients with untreated, symptomatic myeloma were assigned to receive lenalidomide 25 mg on days 1󈞁 plus dexamethasone 40 mg on days 1𔃂, 9󈝸, and 17󈞀 of a 28-day cycle (high dose), or lenalidomide given on the same schedule with dexamethasone 40 mg on days 1, 8, 15, and 22 of a 28-day cycle (low dose). After four cycles, patients could discontinue therapy to pursue stem-cell transplantation or continue treatment until disease progression. The primary endpoint was response rate after four cycles, assessed with European Group for Blood and Bone Marrow Transplant criteria.

The researchers found that 79% of 214 patients receiving high-dose therapy and 68% of 205 patients on low-dose therapy had complete or partial response within four cycles. However, at the second interim analysis at 1 year, overall survival was 96% in the low-dose dexamethasone group compared with 87% in the high-dose group. As a result, the trial was stopped and patients on high dose therapy were crossed over to low-dose therapy. 117 (52%) patients on the high-dose regimen had grade 3 or worse toxic effects in the first 4 months, compared with 76 (35%) of the 220 on the low-dose regimen for whom toxicity data were available. 12 (5%) of 222 on high dose and one (<1%) of 220 on low-dose dexamethasone died in the first four months. The three most common grade three or higher toxicities were deep-vein thrombosis--57 (26%) of 223 versus 27 (12%) of 220; infections including pneumonia--35 (16%) of 223 versus 20 (9%) of 220; and fatigue--33 (15%) of 223 versus 20 (9%) of 220, respectively.

The authors say: "High-dose dexamethasone in a community-setting seems more toxic than low-dose dexamethasone, with more early deaths in the first 4 months, increased risk of thromboembolic complications, and higher overall risk of serious adverse events, particularly in patients older than 65 years."

They conclude: "This trial...shows that low-dose dexamethasone in conjunction with lenalidomide is an active regimen for newly diagnosed myeloma with acceptable toxicity and low early mortality."

They add*: "The results of this trial show that the use of high-dose dexamethasone is not needed for the most part in the context of new active agents for myeloma, and as a result almost all current phase 3 trials have adopted low-dose dexamethasone as the standard in combination regimens."

In an accompanying Reflection and Reaction comment, Professor Antonio Palumbo and Dr Francesca Gay, Divisione di Ematologia dell'Universita di Torino, Turin , Italy say: "The high efficacy and good tolerability of lenalidomide plus low-dose dexamethasone as initial therapy for myeloma has thus been established."

They conclude: "Further randomised phase 3 studies, comparing this regimen with current standards of care such as melphalan-prednisone-thalidomide or melphalan-prednisone-bortezomib, are still needed to verify whether lenalidomide plus low-dose dexamethasone can become a new standard of care for patients with myeloma, and whether the optimal therapeutic strategy should be long-term treatment with lenalidomide and steroids or short-term treatment followed by consolidation with autologous transplantation."
-end-
Professor S Vincent Rajkumar, Mayo Clinic, Rochester, MN, USA. T) +1 507 284-5580 E) rajkumar.vincent@mayo.edu

Professor Antonio Palumbo and Dr Francesca Gay, Divisione di Ematologia dell'Universita di Torino, Turin, Italy. T) +39 011 6336107 E) appalumbo@yahoo.com

For full Article and Reflection and Reaction, see: http://press.thelancet.com/tlomyeloma.pdf

Note to editors: *quote direct from authors and cannot be found in text of Article

Lancet

Related Multiple Myeloma Articles from Brightsurf:

Penn Study supports use of radiation before CAR therapy for multiple myeloma
Administering radiation therapy to multiple myeloma patients waiting for CAR T cells to be manufactured was found to be safe and undisruptive to CAR T therapy.

New multiple myeloma therapy shows promise in preclinical study
A new alpha-radioimmunotherapy, 212Pb-anti-CD38, has proven effective in preventing tumor growth and increasing survival in multiple myeloma tumor-bearing mice, according to new research published in the July issue of The Journal of Nuclear Medicine.

A safer cell therapy harnesses patient T cells to fight multiple myeloma
A treatment for multiple myeloma that harnesses the body's cancer-fighting T cells was safe in humans and showed preliminary signs of effectiveness, according to a clinical trial involving 23 patients with relapsed or treatment-resistant disease.

Colorado tool, My-DST, may pick best multiple myeloma treatment
Response of liquid biopsies to approved drugs can help show resistance, predict response.

Case study: Treating COVID-19 in a patient with multiple myeloma
A case study of a patient in Wuhan, China, suggests that the immunosuppressant tocilizumab may be an effective COVID-19 treatment for very ill patients who also have multiple myeloma and other blood cancers.

New drug could reverse treatment resistance in advanced multiple myeloma
Researchers at the VU University Medical Center in the Netherlands have tested a new drug in patient samples and mice with multiple myeloma and discovered that it was effective even in advanced disease -- a point when many patients currently run out of options.

Single gene cluster loss may contribute to initiation/progression of multiple myeloma
The loss of one copy of the miR15a/miR16-1 gene cluster promoted initiation and progression of multiple myeloma in mice.

New CAR-T target yields promising results for multiple myeloma
In research published today in the journal Nature Communications, Utah-based scientists describe a novel way to treat cancers using chimeric antigen receptor (CAR) T cell therapy.

BCMA-targeted immunotherapy can lead to durable responses in multiple myeloma
An experimental, off-the-shelf immunotherapy that combines a targeted antibody and chemotherapy can lead to potentially durable responses in multiple myeloma patients whose disease has relapsed or is resistant to other standard therapies.

Study finds racial disparities in treatment of multiple myeloma patients
Among patients with multiple myeloma, African-Americans and Hispanics start treatment with a novel therapy significantly later than white patients, according to a new study published today in Blood Advances.

Read More: Multiple Myeloma News and Multiple Myeloma Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.